Phase 4 N=50 Effect of Locally-Applied Simvastatin on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients
Periodontal Diseases
Primary: Change in Clinical Attachment Level (CAL) — 7.0; 6.9 millimeters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=20 Esophageal Food Impaction
Esophageal Food Bolus Obstruction
Primary: Patients Condition at Discharge — 2; 15 Participants
Phase 4 N=93 Embrace TDD: Post-Market Study to Evaluate Intrathecal Morphine as an Alternative to Systemic Opioids for Chronic Pain
Chronic Non-malignant Pain · Chronic Pain · Pain, Back
Primary: Number of Participants With Clinical Success at the 6-Month Visit — 25 Participants
Phase 4 N=25 Ketamine for Older Adults Pilot
Treatment Resistant Depression · Refractory Depression · Therapy-Resistant Depression
Primary: Remission From Depression — 6; 4 Participants
Phase 4 N=13 Bowel Care and Cardiovascular Function After Spinal Cord Injury
Spinal Cord Injury
Primary: Blood Pressure Change During Bowel Care — 90.5; 80 mmHg
Phase 4 N=25 Rheumatoid Arthritis Memory B Cells and Abatacept
Rheumatoid Arthritis
Primary: CDAI Score — 36.06 score on a scale
Phase 4 N=112 High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population
Helicobacter Pylori Infection
Primary: Number of Participant With Eradication of Disease — 37; 42 Participants
Phase 4 N=160 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults
SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 1 — 7.6; 0.0; 5.9; 0.0 Percentage of participants
Phase 4 N=30 Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO
Extracorporeal Membrane Oxygenation Complication · Pediatric ALL · Anticoagulants
Primary: Percentage of Time Spent at Goal Anticoagulation — 0.63; 0.49 percentage of time
Phase 4 N=12 Analysis of Crushed and Whole Tablet Genvoya
Healthy Volunteers
Primary: Area Under the Curve From 0 to Infinity (AUC0-∞) for EVG — 24219; 26948 ng*h/mL
Phase 4 N=80 Fast Track Total Knee Arthroplasty: Local Infiltration Analgesia vs Femoral Nerve Block
Arthroplasty, Replacement, Knee
Primary: Stair Climbing Task (SCT) — 14.3; 13.8 seconds
Phase 4 N=74 Oxygen Versus PAP for Sleep Apnea in Heart Failure
Heart Failure · Sleep Apnea Syndromes
Primary: Left Ventricular Ejection Fraction — 1.63; 1.69; 4.42 percent of LV diastolic volume
Phase 4 N=100 A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
Spondylitis, Ankylosing · Arthritis, Psoriatic
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 10; 18 Participants
Phase 4 N=34 Bone Health in Aging HIV Infected Women
Osteoporosis · HIV · Menopause
Primary: Percent Change in Bone Mineral Density From Baseline at the Lumbar Spine — 1.97; -2.32; 2.33; 0.7 Percent Change
Phase 4 N=31 Linagliptin's Effect on CD34+ Stem Cells
Type 2 Diabetes · Impaired Renal Function
Primary: Cellular Markers — 1.48; 2.48; 1.43; 2.4 Fold Change